Palisade Bio, Inc. (PALI) Reports In-Line Q3 EPS

Palisade Bio, Inc. (NASDAQ: PALI) reported Q3 EPS of ($0.08), in-line with the analyst estimate of ($0.08). Revenue for the quarter came in at $0 versus the consensus estimate of $0 .

For earnings history and earnings-related data on Palisade Bio, Inc. (PALI) click here.

You May Also Be Interested In

• JPMorgan raises S&P 500 target to 7,800, says earnings revision ’unprecedented’
• Benchmark Reiterates Hold Rating on Old Dominion Freight Line (ODFL) as 'Quality Largely Priced in'
• Crown Crafts (CRWS) Reports Q4 EPS of $0.03